JP2022523548A5 - - Google Patents

Info

Publication number
JP2022523548A5
JP2022523548A5 JP2021552571A JP2021552571A JP2022523548A5 JP 2022523548 A5 JP2022523548 A5 JP 2022523548A5 JP 2021552571 A JP2021552571 A JP 2021552571A JP 2021552571 A JP2021552571 A JP 2021552571A JP 2022523548 A5 JP2022523548 A5 JP 2022523548A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
therapeutic agent
weight
biodegradable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552571A
Other languages
English (en)
Japanese (ja)
Other versions
JP7570342B2 (ja
JP2022523548A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021136 external-priority patent/WO2020181060A1/en
Publication of JP2022523548A publication Critical patent/JP2022523548A/ja
Publication of JP2022523548A5 publication Critical patent/JP2022523548A5/ja
Priority to JP2024176400A priority Critical patent/JP7852008B2/ja
Priority to JP2024176401A priority patent/JP7838047B2/ja
Application granted granted Critical
Publication of JP7570342B2 publication Critical patent/JP7570342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552571A 2019-03-05 2020-03-05 眼の疾患又は障害を治療するための医薬組成物 Active JP7570342B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024176400A JP7852008B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176401A JP7838047B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814198P 2019-03-05 2019-03-05
US62/814,198 2019-03-05
PCT/US2020/021136 WO2020181060A1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024176400A Division JP7852008B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176401A Division JP7838047B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Publications (3)

Publication Number Publication Date
JP2022523548A JP2022523548A (ja) 2022-04-25
JP2022523548A5 true JP2022523548A5 (cg-RX-API-DMAC7.html) 2023-03-08
JP7570342B2 JP7570342B2 (ja) 2024-10-21

Family

ID=72337143

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021552571A Active JP7570342B2 (ja) 2019-03-05 2020-03-05 眼の疾患又は障害を治療するための医薬組成物
JP2024176400A Active JP7852008B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176401A Active JP7838047B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024176400A Active JP7852008B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176401A Active JP7838047B2 (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Country Status (9)

Country Link
US (2) US12478577B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934646A4 (cg-RX-API-DMAC7.html)
JP (3) JP7570342B2 (cg-RX-API-DMAC7.html)
CN (3) CN118304422A (cg-RX-API-DMAC7.html)
AU (1) AU2020232314C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017436A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132635A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021010599A (cg-RX-API-DMAC7.html)
WO (1) WO2020181060A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3132635A1 (en) 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
CN115066232B (zh) 2020-02-06 2024-12-10 视尔普斯眼科公司 用于治疗眼病的组合物和方法
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
WO2021207486A1 (en) * 2020-04-08 2021-10-14 Aerie Pharmaceuticals, Inc. Treatments
BR112023022705A2 (pt) 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
US20240239750A1 (en) 2021-05-05 2024-07-18 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
JP2026520094A (ja) 2023-04-11 2026-06-22 オキュラ セラピューティクス,インコーポレイテッド アキシチニブ多形ivを含む眼科インプラント
IL330178A (en) 2024-01-03 2026-08-01 LYOTROPIC DELIVERY SYSTEMS Ltd Topical formulations for delivering active ingredients to the back of the eye
AU2025217596A1 (en) 2024-02-05 2026-08-13 Sun Pharmaceutical Industries Limited Ophthalmic compositions of tyrosine kinase inhibitors and their uses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5445130B2 (ja) * 2006-05-02 2014-03-19 メディバス エルエルシー 眼の外部または内部への眼科用薬剤の送達法
WO2009130332A1 (en) 2008-04-25 2009-10-29 Dsm Ip Assets B.V. Particles comprising polymers with thioester bonds
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
CN107656332B (zh) * 2010-06-22 2021-10-15 东洋纺株式会社 液晶显示装置、偏振板及偏振片保护膜
BR112013018739A2 (pt) * 2010-12-29 2019-09-24 Jade Therapeutics Inc sistema de distribuição de medicamento ocular
US20140179802A1 (en) * 2011-05-02 2014-06-26 Dsm Ip Assets B.V. Fiber comprising a biodegradable polymer
WO2012150255A1 (en) * 2011-05-02 2012-11-08 Dsm Ip Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
HK1205461A1 (zh) * 2012-02-22 2015-12-18 Trustees Of Tufts College 用於眼部传输治疗剂的组合物和方法
WO2014053542A1 (en) 2012-10-02 2014-04-10 Dsm Ip Assets B.V. Drug delivery composition comprising proteins and biodegradable polyesteramides
JP6303199B2 (ja) 2012-10-24 2018-04-04 ディーエスエム アイピー アセッツ ビー.ブイ. 薬物送達のためのポリエステルアミドコポリマーを含む繊維
EP2956096A1 (en) * 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
WO2014165308A2 (en) 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
WO2015126477A1 (en) 2013-11-08 2015-08-27 Tyrx, Inc. Polymeric drug delivery system for treating surgical complications
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
EP3082761A2 (en) * 2013-12-20 2016-10-26 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
US9931306B2 (en) 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye
CA2969171C (en) * 2014-12-18 2023-12-12 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017120600A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
US20180117148A1 (en) * 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
CA3132635A1 (en) 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders

Similar Documents

Publication Publication Date Title
AU2007248143B2 (en) A sustained-release intraocular implant comprising a vasoactive agent
AU2011284589B2 (en) Compounds for the treatment/prevention of ocular inflammatory diseases
CA2653902C (en) Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
CN104185472B (zh) 4‑孕甾烯‑11β‑17‑21‑三醇‑3,20‑二酮衍生物的药物组合物和使用方法
BR112012018134B1 (pt) Uso de um agente terapêutico e implante de liberação sustentada biodegradável para tratar uma condição ocular
BRPI0613401B1 (pt) Composição oftálmica compreendendo derivados de glicocorticoides que penetram seletivamente nos tecidos do segmento posterior
BRPI0617414A2 (pt) mÉtodo para tratamento de formas primÁrias e secundÁrias de glaucoma
JP2020121985A5 (cg-RX-API-DMAC7.html)
JP6752276B2 (ja) 眼炎症状態を処置する際に使用するための、インテグリンα4アンタゴニストを含む薬学的組成物
JP2025004161A (ja) 眼の疾患又は障害を治療するための医薬組成物
JP2015506983A5 (cg-RX-API-DMAC7.html)
JP2019524679A5 (cg-RX-API-DMAC7.html)
US20060154910A1 (en) Use of steroids to treat ocular disorders
JP7571037B2 (ja) 眼表面疼痛を治療する方法
US10350223B2 (en) Compositions and methods for treating ocular diseases
CN100431544C (zh) 用于治疗病理性眼血管生成的糖皮质激素制剂
JP2016050181A (ja) 血管炎治療剤
US20250387410A1 (en) Treatment of anti-vegf refractory ophthalmic retinal eye conditions
US20090181933A1 (en) Use of steroids to treat persons suffering from ocular disorders
JP2025507416A5 (cg-RX-API-DMAC7.html)
EP1781301A2 (en) Angiostatic agents for controlling choroidal neovascularisation after ocular surgery or trauma
Misra et al. Comparative evaluation of the antiinflammatory effect of topical 0.1% dexamethasone sodium and topical 1% prednisolone acetate eye drops after small incision cataract surgery in Indian eyes
PT2319517E (pt) Utilização de pró-fármacos para administração ocular por via intra-vítrea